HK1129226A1 - - Google Patents
Info
- Publication number
- HK1129226A1 HK1129226A1 HK09108423.1A HK09108423A HK1129226A1 HK 1129226 A1 HK1129226 A1 HK 1129226A1 HK 09108423 A HK09108423 A HK 09108423A HK 1129226 A1 HK1129226 A1 HK 1129226A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- receptor regulation
- inhibiting
- noradrenalin
- reuptake
- regulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006027229A DE102006027229A1 (de) | 2006-06-09 | 2006-06-09 | 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
PCT/EP2007/005098 WO2007141039A1 (de) | 2006-06-09 | 2007-06-08 | 1,3-disubstituierte 4-methyl-1 h-pyrrol-2-carbonsäureamide und ihre verwendung zur herstellung von arzneimitteln |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1129226A1 true HK1129226A1 (es) | 2009-11-20 |
Family
ID=38564355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09108423.1A HK1129226A1 (es) | 2006-06-09 | 2009-09-14 |
Country Status (26)
Country | Link |
---|---|
US (1) | US7968591B2 (es) |
EP (1) | EP2035375B1 (es) |
JP (1) | JP5156011B2 (es) |
KR (1) | KR20090016016A (es) |
CN (1) | CN101500994B (es) |
AT (1) | ATE496026T1 (es) |
AU (1) | AU2007256373B2 (es) |
BR (1) | BRPI0712918A2 (es) |
CA (1) | CA2653526A1 (es) |
CY (1) | CY1111429T1 (es) |
DE (2) | DE102006027229A1 (es) |
DK (1) | DK2035375T3 (es) |
EC (1) | ECSP088948A (es) |
ES (1) | ES2355766T3 (es) |
HK (1) | HK1129226A1 (es) |
HR (1) | HRP20110065T1 (es) |
IL (1) | IL195409A (es) |
MX (1) | MX2008015185A (es) |
NO (1) | NO20090073L (es) |
NZ (1) | NZ573289A (es) |
PL (1) | PL2035375T3 (es) |
PT (1) | PT2035375E (es) |
RU (1) | RU2463294C2 (es) |
SI (1) | SI2035375T1 (es) |
WO (1) | WO2007141039A1 (es) |
ZA (1) | ZA200810031B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299115B2 (en) * | 2007-06-08 | 2012-10-30 | Debnath Bhuniya | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
CN101597278B (zh) | 2008-06-04 | 2013-04-17 | 中国中化股份有限公司 | 酰胺类化合物及其制备与应用 |
WO2010044054A1 (en) * | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
TW201416348A (zh) * | 2012-08-29 | 2014-05-01 | Gruenenthal Chemie | 以氟甲基取代之吡咯甲醯胺 |
JP2016540823A (ja) | 2013-12-19 | 2016-12-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | フルオロ置換ピロールカルボキサミドiv |
AU2014365741A1 (en) * | 2013-12-19 | 2016-05-26 | Grünenthal GmbH | Fluoromethyl-substituted pyrrole carboxamides as CaV2.2 calcium channel blockers |
JP2016540821A (ja) * | 2013-12-19 | 2016-12-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | フルオロメチル置換ピロールカルボキサミドiii |
KR101613245B1 (ko) * | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
WO2023115002A1 (en) * | 2021-12-16 | 2023-06-22 | Terran Biosciences Inc. | Analogs of 4-bromo-2,5-dimethoxyphenethylamine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2636063B1 (fr) * | 1988-09-05 | 1993-04-30 | Centre Nat Rech Scient | Composes phenylpyrroliques utiles en tant que medicaments, leur preparation et leur application |
GB9216009D0 (en) * | 1992-07-28 | 1992-09-09 | Almirall Lab | New indol derivatives |
DE4412334A1 (de) * | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
EP0957099B1 (en) * | 1998-04-15 | 2002-11-20 | Pfizer Products Inc. | Heterocyclic carboxamides |
JP4316232B2 (ja) * | 2001-12-28 | 2009-08-19 | 武田薬品工業株式会社 | アンドロゲン受容体拮抗剤 |
WO2004018455A1 (en) * | 2002-08-23 | 2004-03-04 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
AR044586A1 (es) * | 2003-06-04 | 2005-09-21 | Aventis Pharma Sa | Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion |
DE102004024772A1 (de) * | 2004-05-17 | 2005-12-22 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
-
2006
- 2006-06-09 DE DE102006027229A patent/DE102006027229A1/de not_active Withdrawn
-
2007
- 2007-06-08 AU AU2007256373A patent/AU2007256373B2/en not_active Ceased
- 2007-06-08 WO PCT/EP2007/005098 patent/WO2007141039A1/de active Application Filing
- 2007-06-08 EP EP07725929A patent/EP2035375B1/de active Active
- 2007-06-08 RU RU2008151722/04A patent/RU2463294C2/ru not_active IP Right Cessation
- 2007-06-08 KR KR1020097000540A patent/KR20090016016A/ko not_active Application Discontinuation
- 2007-06-08 CN CN2007800294681A patent/CN101500994B/zh not_active Expired - Fee Related
- 2007-06-08 DK DK07725929.9T patent/DK2035375T3/da active
- 2007-06-08 JP JP2009513607A patent/JP5156011B2/ja not_active Expired - Fee Related
- 2007-06-08 CA CA002653526A patent/CA2653526A1/en not_active Abandoned
- 2007-06-08 MX MX2008015185A patent/MX2008015185A/es active IP Right Grant
- 2007-06-08 BR BRPI0712918-1A patent/BRPI0712918A2/pt not_active IP Right Cessation
- 2007-06-08 DE DE502007006315T patent/DE502007006315D1/de active Active
- 2007-06-08 PT PT07725929T patent/PT2035375E/pt unknown
- 2007-06-08 NZ NZ573289A patent/NZ573289A/en not_active IP Right Cessation
- 2007-06-08 PL PL07725929T patent/PL2035375T3/pl unknown
- 2007-06-08 SI SI200730570T patent/SI2035375T1/sl unknown
- 2007-06-08 AT AT07725929T patent/ATE496026T1/de active
- 2007-06-08 ES ES07725929T patent/ES2355766T3/es active Active
-
2008
- 2008-11-20 IL IL195409A patent/IL195409A/en not_active IP Right Cessation
- 2008-11-25 ZA ZA200810031A patent/ZA200810031B/xx unknown
- 2008-12-09 EC EC2008008948A patent/ECSP088948A/es unknown
- 2008-12-09 US US12/331,011 patent/US7968591B2/en not_active Expired - Fee Related
-
2009
- 2009-01-06 NO NO20090073A patent/NO20090073L/no not_active Application Discontinuation
- 2009-09-14 HK HK09108423.1A patent/HK1129226A1/xx not_active IP Right Cessation
-
2011
- 2011-01-28 HR HR20110065T patent/HRP20110065T1/hr unknown
- 2011-02-08 CY CY20111100145T patent/CY1111429T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP088948A (es) | 2009-01-30 |
US20090137573A1 (en) | 2009-05-28 |
CY1111429T1 (el) | 2015-08-05 |
NZ573289A (en) | 2010-07-30 |
AU2007256373B2 (en) | 2012-04-19 |
BRPI0712918A2 (pt) | 2012-10-02 |
MX2008015185A (es) | 2008-12-09 |
US7968591B2 (en) | 2011-06-28 |
KR20090016016A (ko) | 2009-02-12 |
ES2355766T3 (es) | 2011-03-30 |
DK2035375T3 (da) | 2011-02-21 |
ZA200810031B (en) | 2009-08-26 |
IL195409A0 (en) | 2009-08-03 |
EP2035375A1 (de) | 2009-03-18 |
RU2008151722A (ru) | 2010-07-20 |
PL2035375T3 (pl) | 2011-06-30 |
SI2035375T1 (sl) | 2011-05-31 |
WO2007141039A1 (de) | 2007-12-13 |
HRP20110065T1 (hr) | 2011-03-31 |
RU2463294C2 (ru) | 2012-10-10 |
DE102006027229A1 (de) | 2007-12-20 |
AU2007256373A1 (en) | 2007-12-13 |
JP2010509187A (ja) | 2010-03-25 |
PT2035375E (pt) | 2011-04-06 |
CA2653526A1 (en) | 2007-12-13 |
ATE496026T1 (de) | 2011-02-15 |
IL195409A (en) | 2013-06-27 |
NO20090073L (no) | 2009-03-06 |
EP2035375B1 (de) | 2011-01-19 |
CN101500994A (zh) | 2009-08-05 |
JP5156011B2 (ja) | 2013-03-06 |
DE502007006315D1 (de) | 2011-03-03 |
CN101500994B (zh) | 2012-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1129226A1 (es) | ||
JO2686B1 (en) | Vehicles | |
MX2009005462A (es) | Analogos de 7,8-saturados-4,5-epoxi-morfinano. | |
MX2009007180A (es) | Agonistas del receptor acoplado a la proteina g de la piperidina. | |
MX2008012400A (es) | Azolopirimidinas como inhibidores de actividad de cannabinoide 1. | |
MX2009005461A (es) | N-oxidos de analogos de 4,5-epoxi-morfinano. | |
HK1158192A1 (en) | Piperidine gpcr agonists | |
MEP6808A (xx) | Priperidinoilpirodolini agonisti receptora menalokortina tipa 4 | |
MX2009008159A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
MY153915A (en) | Organic compounds | |
MX2009003611A (es) | Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y metodos de uso. | |
MY141024A (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
MX2010001576A (es) | Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6). | |
HK1157329A1 (en) | Piperidinyl gpcr agonists | |
MX2012002366A (es) | Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. | |
TW200720260A (en) | Prokineticin 1 receptor antagonists | |
MX2009005460A (es) | (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano. | |
MY147649A (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
NO20073941L (no) | Dihydroimidazotiazolderivater | |
MX2009004983A (es) | Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion. | |
UA106200C2 (uk) | Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину | |
TW200740766A (en) | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands | |
MY152685A (en) | Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments | |
MY152040A (en) | Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments | |
TW200616637A (en) | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20150608 |